Dr. Nagla Abdel Karim

From Personal Loss to Purpose: Nagla Abdel Karim, MD, Joins the GW Cancer Center From her father’s illness to groundbreaking clinical trials, Dr. Nagla Karim joins GW with a mission to advance lung cancer treatment and compassionate, whole-person care.

cancercenter.gwu.edu/news/persona...

bsky.app/profile/iasl...

More to go with our @iaslc.bsky.social Podcast in Arabic!

I am honored to present today 9/6 our oligometastatic subcommittee updates @IASLC #wclc2025 workshop 2:30 PM WS14 From Guidelines to Implementation in NSCLC: Pertinent Considerations of Adherence to Consensus Standards of Care in Clinical Practice
Location: Room 09

Thank you @simonheeke.bsky.social

It is a great honor to be nominated for #IASLC Board Elections. I appreciate your consideration to vote and support my nomination.

It was a great pleasure to be part of the SCLC panel at “Call to Action” New York Summit.

It’s always a great pleasure to be part of @iaslc.bsky.social #TTLC25

It has been a great pleasure to present “Immunotherapy and Inflammation: Impact on Cardiovascular Health” #ACCCardioOnc! Cardio-Oncology Conference in DC.

Stay Tuned for the updates in Thoracic Neuroendocrine Tumors #NETChatter

Lung Cancer Alliance in Arabic-Speaking MENA (LCAM).
This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA

On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Review of how to manage challenging situations.

It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.

Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.

Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign

www.wral.com/lifestyle/he...

@younglungcancer.bsky.social

Ensuring Virtual Vigilance in Decentralized Clinical Trials This Viewpoint discusses the increased use of decentralized clinical trials (DCTs) to improve efficiency in health research, highlights a number of risks to research rigor inherent in DCTs, and sugges...

Authors discuss a few of the many, many challenges in trying to make "decentralized" clinical trials happen
jamanetwork.com/journals/jam...

I would like to wait for the results of S1827 since it is the randomized prospective study designed to learn if PCI is needed versus Brain MRI surveillance.

Superb opinion piece on PCI in SCLC: do we need it in the IO era?

Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms

#LCSM #MedSky #OncSky

www.sciencedirect.com/science/arti...

www.jto.org/article/S155...

It is pretty feasible to personalize therapy for small cell lung cancer.
It is about time to improve the predictive biomarkers & novel therapies for SCLC.